AzurRx BioPharma (AZRX) Reaches New 1-Year Low at $1.87

Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) hit a new 52-week low on Thursday . The company traded as low as $1.87 and last traded at $1.90, with a volume of 100 shares changing hands. The stock had previously closed at $1.99.

A number of analysts recently weighed in on AZRX shares. CIBC started coverage on shares of AzurRx BioPharma in a report on Wednesday, October 17th. They issued an “outperform” rating and a $6.00 price target for the company. HC Wainwright set a $8.00 price target on shares of AzurRx BioPharma and gave the company a “buy” rating in a report on Friday, November 2nd. ValuEngine raised shares of AzurRx BioPharma from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Finally, Oppenheimer started coverage on shares of AzurRx BioPharma in a report on Wednesday, October 17th. They issued an “outperform” rating and a $6.00 price target for the company.

Several institutional investors have recently modified their holdings of the stock. 683 Capital Management LLC acquired a new stake in shares of AzurRx BioPharma in the second quarter valued at approximately $1,284,000. Ardsley Advisory Partners boosted its stake in AzurRx BioPharma by 66.3% in the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock valued at $440,000 after acquiring an additional 54,697 shares during the last quarter. Finally, Opaleye Management Inc. bought a new position in AzurRx BioPharma in the second quarter valued at approximately $417,000. 18.93% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “AzurRx BioPharma (AZRX) Reaches New 1-Year Low at $1.87” was reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2018/12/08/azurrx-biopharma-azrx-reaches-new-1-year-low-at-1-87.html.

About AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Read More: Asset Allocation, Balancing Your Investments

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply